XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Equity Incentive Plan (Tables)
6 Months Ended
Jun. 30, 2024
Schedule of Additional Information on Stock Option Grants And Vesting

The following table summarizes additional information on stock option grants and vesting (in thousands):

 

 

 

2019 Plan

 

 

2019 Plan

 

 

 

Three Months Ended June 30, 2024

 

 

Three Months Ended June 30, 2023

 

 

Six Months Ended June 30, 2024

 

 

Six Months Ended June 30, 2023

 

Total fair value of options vested

 

$

327

 

 

$

217

 

 

$

1,767

 

 

$

1,465

 

Stock Based Compensation Expense Included In Condensed Consolidated Statements of Comprehensive Loss

Stock-based compensation expense is included in the Company’s Condensed Consolidated Statements of Comprehensive Loss within the following line items (in thousands):

 

 

 

Three Months Ended June 30, 2024

 

 

Three Months Ended June 30, 2023

 

 

Six Months Ended June 30, 2024

 

 

Six Months Ended June 30, 2023

 

Cost of revenues

 

$

228

 

 

$

244

 

 

$

424

 

 

$

471

 

General and administrative

 

 

349

 

 

 

453

 

 

 

738

 

 

 

897

 

Research and development

 

 

101

 

 

 

94

 

 

 

188

 

 

 

170

 

Sales and marketing

 

 

89

 

 

 

86

 

 

 

165

 

 

 

172

 

Total

 

$

767

 

 

$

877

 

 

$

1,515

 

 

$

1,710

 

Restricted Stock Units [Member]  
Schedule of RSUs Activity Under 2019 Plan

The following table summarizes the Company’s RSU activity for performance based RSUs awarded to employees and for time-based RSUs granted to non-employee directors under the 2019 Plan:

 

Description

 

RSUs
Outstanding

 

Outstanding at December 31, 2023

 

 

2,429,289

 

Granted

 

 

 

Vested

 

 

(577,659

)

Forfeited

 

 

(130,900

)

Expired

 

 

 

Outstanding at June 30, 2024

 

 

1,720,730

 

2019 Plan [Member]  
Schedule of Stock Option Activity Under 2019 Plan

The following table summarizes the Company’s stock option activity under the 2019 Plan:

 

Description

 

Options
Outstanding

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Term (Years)

 

Options outstanding, December 31, 2023

 

 

6,529,092

 

 

$

6.88

 

 

 

6.60

 

Granted

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(4,501

)

 

 

2.33

 

 

 

 

Expired

 

 

(70,181

)

 

 

8.12

 

 

 

 

Options outstanding, June 30, 2024

 

 

6,454,410

 

 

$

6.87

 

 

 

6.56

 

Options vested and exercisable, June 30, 2024

 

 

5,428,010

 

 

$

7.63

 

 

 

6.20

 

Options vested and expected to vest, June 30, 2024

 

 

6,454,410

 

 

$

6.87

 

 

 

6.56

 

_______________________________

(1)
Aggregate intrinsic value (in thousands) represents the difference between the estimated fair value of the underlying Common Stock and the exercise price of outstanding in-the-money options.